This site is intended for healthcare
professionals in Belgium and Luxembourg.

Select a Condition

For your adult patients with
or B-thalassemia-associated anemia

With Reblozyl®▼- the first and only erythroid maturation agent-
you can reduce or even eliminate patients’ red blood cell (RBC)
transfusion dependence. 1-3

Reblozyl®▼ is reimbursed in Belgium as of August 1st 2021 for the treatment of adult

  • with transfusion-dependent anemia due to very low, low or intermediate-risk
    (IPSS-R) myelodysplastic syndrome (MDS) with ring sideroblasts, who had an
    unsatisfactory response to or are ineligible to erythropoietin-based therapy
  • with transfusion-dependent anemia associated with B-thalassemia.

The request has to be submitted via eHealth.

The maximum reimbursed posology is 1,75 mg/kg every 21 days for MDS and 1,25 mg/kg
every 21 days for beta-thalassemia.

Reblozyl®▼ treatment will stop being reimbursed if:

  • there is no reduction of the transfusion burden after 9 weeks (3 cycles) at the
    maximum dose level, if the lack of response cannot be explained otherwise
    (bleeding, surgical intervention, other concomitant disease) or,
  • anytime in case of unacceptable toxicities. 4

▼This medicinal product is subject to additional monitoring. This will allow quick
Identification of new safety information. Healthcare professionals are asked to report any
suspected adverse reactions. Before prescribing Reblozyl®▼, please refer to the SmPC.
View the Eu SmPC in French, SmPC in Dutch.